Hansoh Pharma Wins Breakthrough Therapy Designation in China for Prostate Cancer ADC

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.

Hansoh Pharmaceutical Group said its self-developed B7-H3-targeted antibody-drug conjugate HS-20093 has been granted Breakthrough-Therapy-Designated Drug status by China’s National Medical Products Administration. The proposed indication is for metastatic castration-resistant prostate cancer in patients previously treated with novel endocrine therapy and taxane-based chemotherapy.

The designation underscores Hansoh’s progress in next-generation oncology treatments and could accelerate development and regulatory review of HS-20093. If successfully brought to market, the drug candidate may enhance the group’s oncology portfolio and reinforce its competitive standing in China’s fast-growing innovative cancer drug segment.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative medicines. The group develops oncology and other specialty drugs, leveraging in-house R&D to expand its pipeline and strengthen its position in high-need therapeutic areas.

Average Trading Volume: 9,595,210

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$234.1B

For an in-depth examination of 3692 stock, go to TipRanks’ Overview page.